Real-world study for the efficacy and safety of pegfilgrastim in preventing neutropenia after chemotherapy in breast cancer patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900021399

Enrollment

Unknown

Registered

2019-02-19

Start date

2019-03-02

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

A:Use Jin Youli within 24 hours and within 12 days of the next chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age = 18 years old, gender is not limited; 2. Breast cancer patients diagnosed by histopathology or cytology; 3. Patients who receive or plan to receive chemotherapy; 4. Patients with good mental awareness, understand the clinical Investigate and voluntarily join the study and sign an informed consent for.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women and women who plan to become pregnant during clinical observation; 2. Those who have been confirmed to be allergic to pegfilgrastim or rhG-CSF and/or its excipients.

Design outcomes

Primary

Measure	Time frame
FN incidence;Occurrence and severity of adverse reactions;	—

Secondary

Measure	Time frame
III/IV degree granule deficiency rate and duration;Incidence of dose adjustment for chemotherapy drugs;Incidence of chemotherapy delay;Relative dose strength;Antibiotic use rate;	—

Countries

China

Contacts

Public ContactHong Liu

Tianjin Cancer Hospital

lh713@163.com+86 18622221169

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026